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Abstract
Background: Avian influenza virus H5N1 has demonstrated considerable pandemic potential.
Currently, no effective vaccines for H5N1 infection are available, so passive immunotherapy may
be an alternative strategy. To investigate the possible therapeutic effect of antibody against highly
pathogenic H5N1 virus on a mammal host, we prepared specific equine anti-H5N1 IgGs from
horses vaccinated with inactivated H5N1 virus, and then obtained the F(ab')2 fragments by pepsin
digestion of IgGs.
Methods: The horses were vaccinated with inactivated H5N1 vaccine to prepare anti-H5N1 IgGs.
The F(ab')2 fragments were purified from anti-H5N1 hyperimmune sera by a protocol for 'enhanced
pepsin digestion'. The protective effect of the F(ab')2 fragments against H5N1 virus infection was
determined in cultured MDCK cells by cytopathic effect (CPE) assay and in a BALB/c mouse model
by survival rate assay.
Results: By the protocol for 'enhanced pepsin digestion', total 16 g F(ab')2 fragments were finally
obtained from one liter equine antisera with the purity of over 90%. The H5N1-specific F(ab')2
fragments had a HI titer of 1:1024, and the neutralization titre of F(ab')2 reached 1: 2048. The in
vivo assay showed that 100 μg of the F(ab')2 fragments could protect BALB/c mice infected with a
lethal dose of influenza H5N1 virus.
Conclusion: The availability of highly purified H5N1-specific F(ab')2 fragments may be promising
for treatment of influenza H5N1 infection. Our work has provided experimental support for the
application of the therapeutic equine immunoglobulin in future large primate or human trials.
Background
In recent years, it has become clear that human infections
with highly pathogenic influenza (HPAI) H5N1 viruses
are associated with severe, often fatal disease. In 1997 in
Hong Kong, avian influenza A (H5N1) infected both
chickens and humans. During this outbreak, 18 people
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2003, two cases of avian-like H5N1 influenza virus infec-
tion occurred among members of a Hong Kong family
who had traveled to mainland China; one person recov-
ered, the other died [4]. In 2004 and 2005, HPAI H5N1
outbreaks were reported in several Asian countries, and
these outbreaks were not easily halted. Up to March 1
2006, the total number of confirmed human cases of
influenza H5N1 had amounted to 174, of which 94 were
fatal [5]. It cannot excluded that the additional cases were
ignored in the involved countries due to a lack of clinical
awareness, active surveillance, or diagnostic facilities [6].
In the early epidemic, domestic cats, captive tigers, and
leopards also died from avian influenza H5N1 viruses,
which indicates that H5N1 virus can cross species barriers
[7,8]. More and more mammals may become involved in
this epidemic. The continued circulation of the H5N1
virus in poultry increases its opportunity to adapt to
humans through mutation or genetic reassortment in
humans or intermediate mammalian hosts. Therefore, the
ongoing H5N1 influenza epidemic in Asian bird popula-
tions poses risks to the public as well as to animal health
[9]. In addition, a limited number of possible human-to-
human transmissions of influenza H5N1 have been
reported [10], which should serve as a prewarning of a
future influenza pandemic. A human pandemic with
H5N1 virus could potentially be catastrophic because of
an almost complete lack of antibody-mediated immunity
to the H5 surface protein in most human populations and
the virulence of this viral subtype.
Although vaccines against the H5N1 virus are under
development in several countries, no vaccine is ready for
commercial production. The traditional inactivated vac-
cine production against H5N1 virus is complicated
because of the requirement for high biosafety contain-
ment facilities, and the difficulty, in some cases, to obtain
high virus yields in embryonated eggs due to the virus'
pathogenicity [11,12]. Several other approaches have
been used in an attempt to overcome these obstacles,
including the use of reverse genetics techniques, genera-
tion of recombinant hemagglutinin, DNA vaccination
and the use of related apathogenic H5 viruses with and
without different adjuvants [13-16]. However, there is still
a long way to obtain a safe and effective vaccine for pre-
venting H5N1 virus infection in human.
Currently, two classes of drugs are available with antiviral
activity against influenza viruses: the M2 inhibitors
(amantadine and rimantadine), and the neuraminidase
inhibitors (oseltamivir and zanamivir). Some currently
circulating H5N1 strains are fully resistant to the M2
inhibitors [17,18]. For cases of human infection with
H5N1, the neuraminidase inhibitors may improve pros-
pects of survival, if administered early, but the clinical evi-
dence is limited. Antiviral resistance to neuraminidase
inhibitors has been clinically negligible so far but is likely
to be detected during widespread use during a pandemic
[19].
Development of H5N1-specific antibodies may be an
alternative strategy for the treatment of infection and the
prevention and control of future outbreaks. Previous
study has shown that neutralizing Fab fragments of a
hemagglutinin-specific antibody were effective in treating
established influenza A virus infection in mice with severe
combined immunodeficiency [20]. Ramisse et al. also ver-
ified that topical administration of polyvalent plasma-
derived human immunoglobulin and F(ab')2 can protect
BALB/c mice infected with a lethal dose of influenza virus
[21]. Although the genus difference exists between human
and mice, this strategy still deserves our attention in the
treatment of a severe illness such as influenza H5N1.
The practice of administering polyclonal immunoglobu-
lins from hyperimmune sera of animal or human origin
has been used extensively in prophylactic as well as thera-
peutic settings, including rabies and hepatitis [22]. Except-
ing certain viral illnesses like measles, animal sera were
used routinely due to the fact that obtaining sufficient
human convalescent sera for therapeutic purpose was
impractical. In the setting of viral infection, equine antise-
rum has been applied as an antiviral regimen to control
infection by ebola [23], rabies [24,25], hepatitis B virus
[26,27] and HIV [28,29]. The equine antiserum possibly
results in the anaphylactoid severe acute side effects
induced by contaminants including serum proteins, Fc
and other fragments or aggregates [30,31]. Non-tradi-
tional antibody production methods, however can assure
safety and availability of heterogenous antisera [32].
Jones and Landon reported that high yields of F(ab')2 frag-
ments with high purity can be obtained from ovine antise-
rum by a protocol for 'enhanced pepsin digestion' [33]. To
investigate the therapeutic efficacy of equine antibody to
H5N1 virus, we isolated serum IgGs from horses vacci-
nated with inactivated H5N1 vaccine and prepared
F(ab')2 fragments by this protocol. We report herein the
protective effects of F(ab')2 against H5N1 virus infection




Influenza virus A/Chicken/Guangdong/04 (H5N1) was
propagated in the allantoic cavity of embryonated hen's
eggs. The titer of infectious virus was determined by limit-
ing dilution in microcultures of Madin-Darby canine kid-
ney (MDCK) cells and was expressed as the 50% tissuePage 2 of 7
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cally contained ~108.5 TCID50s/ml. Aliquots were stored
frozen (-70°C) and used once for infection of mice or
determination of antibody-mediated virus neutralization
activity. All operations with H5N1 virus were performed
in a bio-safety level 3 (BSL-3) laboratory.
Antiserum
An inactivated influenza H5N1 vaccine strain isolated in
2003, provided by the South China Agricultural Univer-
sity, was performed for four times immunization of
health horses according to the operating procedures rec-
ommended by State Food and Drug Administration
(SFDA) (not shown). The hyperimmune sera from immu-
nized horses were collected and stored at -80°C until
used.
Preparation of equine F(ab')2 fragments
To prepare the F(ab')2 fragments, 500 ml hyperimmune
sera from immunized horses were purified as described in
[33]. The hyperimmue sera were adjusted to pH 3.5. Acid-
ified equine antisera were digested with pepsin (porcine,
Sigma) solution (50 mg/mL pepsin in distilled water,
stored frozen at -20°C) at 37°C for 36 h. The digestion
was terminated by titrating to pH 6.0 with the 50 mM pip-
erazine base solution. Centrifuge at 2750 × g (4–10°C) to
remove the precipitate. Tangential flow diafiltration was
then performed to remove the bulk of low molecular
weight digestion products. The digested antisera were
washed with at least 15 volumes of diafiltration buffer/
buffer A (20 mM piperazine, 150 mM NaCl, pH 6.0) on
the tangential flow difiltration rig (VivaFlow50, Vivas-
cience) with a 50 cm2, 30 000-Da nominal molecular
weight cut-off membrane and concentrated to ~100 ml
total volume. Diafiltrated digests were then passed
through a column of Q Sepharose Fast Flow to remove the
residual acidic aggregates and pepsin. All the unbound
material, corresponding to the purified F(ab')2, was col-
lected and stored at 4°C. Then eluted fractions (peak I)
were concentrated with the same tangential flow diafiltra-
tion equipment and to obtain the final product with the
desired concentration. The final F(ab')2 products were dis-
solved in PBS (pH 7.0, supplemented with 0.007% mer-
curothiolate), and their protein concentration and purity
were determined by BCA method and folium scan, respec-
tively.
SDS-PAGE
Non-reducing SDS-PAGE gels using the Laemmli buffer
system (1970) [34] were performed to check for traces of
undigested IgG or large partially digested albumin frag-
ments.
ELISA
Total purified F(ab')2 was measured by an indirect
enzyme-linked immunosorbent assay (ELISA) using
whole purified H5N1 as coating antigen in a tetramethyl-
benzidine (TMB) system. Microwell plates were coated
overnight at 4°C with each of the purified influenza
H5N1 virus at 1 μg/mL in carbonate-bicarbonate buffer
(pH 9.6). The wells were washed three times with 0.05%
Tween 20 in PBS (PBS-T) and then blocked with 5% non-
fat milk in PBS-T at 37°C for 1 h. Following three washes
with PBS-T, serum samples diluted were added and incu-
bated at 37°C for 1 h. Following five washes, HRP-conju-
gated goat anti-horse IgG (Sigma) diluted 2000-fold in
PBS-T was added to detect the bound antibodies. Follow-
ing incubation at 37°C for 1 h, the plates were washed as
above and the substrate tetramethylbenzidine (TMB)
solution (Sigma) was added to the wells to generate the
color. After incubation at room temperature for 30 min,
the reaction was stopped by adding 2 mmol/L H2SO4. The
absorbance value at 450 nm (A450) was determined with
an ELISA reader (Model 550, BioRad, USA). Antibody titer
was defined as the highest dilution of F(ab')2 at which the
A450 ratio (A450 of negative serum) was greater than 2.0.
HI test
F(ab')2 fragments were tested for antibodies to the influ-
enza H5N1 virus Guangdong strain by hemagglutination-
inhibition (HI) according to the operating procedures
used in avian influenza virus recommended by World
Health Organization (WHO) in 2002 [35]. HI was
assessed using 25 μl each of a series of F(ab')2 dilutions
1:2, and 25 μl of HA antigen, standardized at 4 hemagglu-
tination units (HAU) by hemagglutination titration, were
added. The mixture was incubated for 1 h at room temper-
ature, 50 μl of 1% chicken erythrocytes were added and
the plate was gently shaken. The HI titer was recorded
after incubation for 1 h at room temperature and is
expressed as the reciprocal of the F(ab')2 dilution that
inhibited hemagglutination.
Virus neutralization activity in vitro
Neutralizing antibody titer of F(ab')2 was determined by
micro-cytopathic effect (CPE) neutralizing test with H5N1
virus Guangdong strain according to WHO protocols [35].
The F(ab')2 fragments against H5N1 virus were diluted in
two-fold serially from 1:10 to 1:5120. The antibody solu-
tions (100 μl) were mixed in 1:1 (v/v) with suspension
containing 100 TCID50 of highly purified H5N1 virus
(108.5 TCID50/ml) particles and incubated at 37°C for 1 h.
The virus-antibody mix was then transferred onto MDCK
cell monolayers in 96-well plates at 37°C for 1 h subse-
quently. Washed with MEM maintenance medium, each
well was added by 100 μl MEM maintenance medium,
and then incubated at 37°C in 5% CO2 incubator. Posi-
tive and negative controls were set as 'virus control' (withPage 3 of 7
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[without virus or F(ab')2] and 'normal horse antibody
control'. CPE status was observed every 24 h for 5 days.
The neutralizing antibody titer was expressed as the recip-
rocal of the highest F(ab')2 dilution which gave 50% neu-
tralization of 100 TCID50 of virus. The experiment was
repeated three times.
Therapeutic activity in vivo
Female BALB/c mice, 6–8 weeks old (provided by the Ani-
mal Centre of Sun Yat-sen University, Guangdong,
China), were housed within separate negative-pressure
stainless steel isolators in a high-containment BSL-3 agri-
culture facility. Feed and water were provided ad libitum.
Approval for animal experiments was obtained from the
institutional animal welfare committee.
The mice were randomized to 4 groups (ten mice per
group) and infected with 50 μl of H5N1 virus (108.5
TCID50/ml) by intranasal route. Twenty-four hours later,
3 groups of mice were injected intraperitoneally with 50,
100, 200 μg anti-H5N1 F(ab')2 fragments, respectively. A
negative control group of mice received normal horse sera
(200 μg). The survival of mice following the lethal chal-
lenge was scored each day for 14 days.
Results
Preparation of F(ab')2 fragments
The equine hyperimmune sera were digested with pepsin.
SDS-PAGE showed that digestion within 36 h completely
eliminated the high molecular weight material (e g. albu-
min and transferrin bands and the intact IgG), and only
F(ab')2 band (~100 kDa) and very low molecular weight
material was observed (Fig. 1). Following digestion, tan-
gential flow diafiltration of the digested material was per-
formed to remove all of the molecular weight lower than
F(ab')2, leaving principally F(ab')2 and a small quantity of
high molecular weight aggregate. Finally, the anion-
exchange chromatography was then performed to remove
The digestion of equine antiserum with pepsin, as assessed by SDS-PAGE (10%) und r on- educing conditionFigure 1
The digestion of equine antiserum with pepsin, as assessed by 
SDS-PAGE (10%) under non-reducing conditions. Digestion 
samples at corresponding time points, with molecular weight 
markers (first lane): 97 kDa, 66 kDa, 45 kDa, 30 kDa, 20.1 
kDa, respectively.
Removal of high molecular weight aggregate and pepsin by anion-exchange chromatographyFigur  2
Removal of high molecular weight aggregate and pepsin by 
anion-exchange chromatography. Q-Sepharose FF ion-
exchange separation of a diafiltrated pepsin digested antise-
rum. Peak I: F(ab')2, Peak II: high molecular weight aggregate 
and Peak III: pepsin.Page 4 of 7
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taminants and pepsin). Diafiltered digests in diafiltration
buffer (20 mM piperazine, 150 mM NaCl, pH 6.0) were
separated into three peaks by anion exchange chromatog-
raphy (Fig. 2). The first peak, which passed straight
through the column, constituting ~90% of the material,
containing the F(ab')2 fragments. Peak II, the acidic high
molecular weight aggregate material was eluted by 200 ml
buffer B. Peak III, the highly acidic pepsin was eluted by
20 ml buffer B. Material from the unbound peak (I) was
then concentrated with a 30-kDa nMWCO ultrafilter and
typically gave a final yield of 16 g F(ab')2/L antisera. The
purity of F(ab')2 fragments reached over 90%, as meas-
ured by the folium scan method. The product obtained
above was dissolved in a suitable volume of PBS to adjust
the protein concentration to 2.0 mg/ml.
ELISA result showed that the specific activity of F(ab')2
fragments reached 1:5120 after pepsin digestion, ultra-fil-
tration and anion-exchange chromatography.
Protective efficacy of anti-H5N1 F(ab')2 in vitro
The purified F(ab')2 was tested for HI activity against the
lethal H5N1, and the HI antibody titer was determined as
1:1024. A virus neutralization assay was also included,
infection of MDCK monolayer cells was carried out as
described in Materials and methods. Fig. 3 displayed the
neutralization photographs at 72 h with the F(ab')2. Com-
pared with cell control (Fig. 3A), under the neutralization
of 1:2048 dilution, the cells presented morphologic
changes with about 50% CPE, which were calculated as
the neutralization titres for F(ab')2 against the Guangdong
H5N1 virus strain. CPE developed in virus controls (Fig.
3B), while anti-H5N1 F(ab')2 could protect MDCK cells
from death of H5N1 virus infection and no CPE was
observed (Fig. 3C).
Effectiveness of passive immunotherapy with equine anti-
H5N1 F(ab')2 administrated intraperitoneally
To verify the presumption that the prepared anti-H5N1
F(ab')2 fragments will have therapeutic efficacy in mam-
mals, we tested the in vivo effectiveness of the F(ab')2 frag-
ments in a BALB/c mouse model that had been proven to
be vulnerable to infection with H5N1 virus by the intrana-
sal route and replicated equally well in the lungs of mice
without prior adaptation [36].
We assayed the therapeutic efficacy of F(ab')2 fragments
against the lethal dose of H5N1 viruses by intraperitoneal
injection of 50, 100, 200 μg F(ab')2 fragments/mouse
using normal horse antibody as a control, 24 h after infec-
tion (Fig. 4). 50 μg of anti-H5N1 F(ab')2 were required to
give 70% protection. 100 and 200 μg of anti-H5N1
F(ab')2 were required to give 100% protection. In contrast,
the antibody-negative control (200 μg of non-immune
equine antibody) could not provide protection and the
mice in this group died completely.
Discussion
Over the past several years, cases of human infection with
highly pathogenic H5N1 virus have raised international
concern that we might face a global influenza pandemic
in the near future. How can we arm ourselves against this
pandemic threat? Although various kinds of vaccines
against H5N1 virus are under development, there is still a
Photographs of micro-cytopathic effect neutralization testsFigure 3
Photographs of micro-cytopathic effect neutralization tests. 
The F(ab')2 against H5N1 virus was diluted into two-fold 
serial dilutions, and incubated with an equal volume of active 
H5N1 virus dilution (100 TCID50). After neutralization, each 
mixture was added to MDCK cell monolayers in micro-
plates, and incubated at 37°C to observe CPE status. These 
photographs showed the morphologic changes of MDCK 
cells at 72 h after infection. (A) Cell control (no CPE); (B) cell 
morphologic changes infected with the H5N1 virus; (C) 
MDCK cells protected from infection of H5N1 virus by anti-
H5N1 F(ab')2.
Efficacy of passive immunotherapy of influenza H5N1 virus in ection by i.p. injection f F(ab')2 at dose of 50, 100 and 200 μg/mouse at 24 h after i tranas l challenge with the influenzaGuangd ng H5N1 virus strainFigure 4
Efficacy of passive immunotherapy of influenza H5N1 virus 
infection by i.p. injection of F(ab')2 at dose of 50, 100 and 200 μg/mouse at 24 h after intranasal challenge with the influenza 
Guangdong H5N1 virus strain.Page 5 of 7
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of H5N1 virus infection is short, and the symptoms are
hard to distinguish from those of the common cold, any
delay in diagnosis and treatment could fatally jeopardize
the patient's life. Once an individual is infected, adminis-
tration of vaccine may be too late to elicit protective
immunity. Meanwhile, we should seek multiple, mutually
supportive intervention strategies to expand our weap-
onry against highly pathogenic H5N1 virus. Thus, it is
imperative to develop a human H5N1 infection antidote
that can provide immediate protection in such cases. In
viral disease, antibodies obtained passively can deliver
instant and short-term protection against infection
regardless of the immune status of the host [37,38].
Development of human antibody against H5N1 virus is
theoretically the ideal strategy to treat infection. However,
it is difficult to obtain immune human donors. The heter-
ogenous antibodies, for example, equine IgGs, have an
advantage in this respect. Furthermore, one theoretically
potential advantage of the polyclonal IgGs is the broader
antigenic coverage and the lower likelihood of emergence
of escape mutants. What's more, the heterogenous antis-
era are relatively economic and readily available upon
request.
In this study, we reported the preparation of equine
H5N1-specific F(ab')2 fragments and we observed their
protective effects against highly pathogenic H5N1 virus
infection in cultured mammalian cells. The in vitro neu-
tralization assay showed that H5N1-specific F(ab')2 had
protective effects on MDCK cells against H5N1 infection.
A novel antidote has to be tested in vivo before entering
clinical application. Accordingly, we evaluated the protec-
tive efficiency of equine H5N1-specific F(ab')2 against the
H5N1 virus infection in a BALB/c mouse model. The
results showed that 100 μg of the F(ab')2 could protect
100% of mice infected with lethal challenge of H5N1
virus, if administrated 24 h after infection. Although the
dose of F(ab')2 used here was relatively high compared
with practical clinical application, this study may provide
experimental data for preclinical studies regarding the
effect of adoptive transfer of antibodies.
Nevertheless, the heterogeneous antibody possibly evokes
a strong host immune response and inhibits its applica-
tion in a clinical setting. The heterology of specific IgGs
can be decreased through the preparation of F(ab')2 frag-
ments by cutting off the Fc fragment. In this study, equine
anti-H5N1 hyperimmune sera were purified by using a
protocol for 'enhanced pepsin digestion'. Equine antisera
were firstly digested with pepsin to remove a small
amount of high molecular weight material. Tangential-
flow diafiltration was then used as a convenient and
highly effective method to remove the bulk of the low
molecular weight contaminants (e.g. albumin, albumin
fragments, and transferrin). However, diafiltration is inef-
fective at removing pepsin. Pepsin will bind to an anion-
exchange matrix in the presence of 150 mM NaCl at pH
6.0. For most F(ab')2 fragments they pass straight through
the column at this salt concentration. Further more, other
acidic residual fragments, including the residual high
molecular weight aggregates, also bind to the column at
this salt concentration and are removed. Anion exchange
was therefore used as a final purification step to remove
the remaining pepsin and high molecular weight aggre-
gates. Final yields of 16 g F(ab')2/L equine anti-H5N1 sera
with a purity of over 90% were obtained, which compares
favorably with the value of 6–14 g F(ab')2/L equine
plasma reported [39]. In addition, this simple, high yield
protocol for processing serum to highly purified F(ab')2
avoids the need for an initial or any subsequent salt pre-
cipitation step and can be utilised for either bench or large
scale production of F(ab')2 notably for immunotherapeu-
tic use.
Until we have an efficacious vaccine, specific anti-H5N1
agents, and effective epidemiologic control measures for
H5N1 virus infection, highly pathogenic H5N1 virus is
likely to be a major health threat to the world. In this arti-
cle, we have attempted to provide an alternative pathway
of prevention and treatment of H5N1 infection, and in
doing so we hope that F(ab')2 purified from equine antise-
rum can play a potent role in combating the H5N1 virus.
H5N1-specific F(ab')2 is polyclonal and polyvalent, so it
may contain a wide variety of antibodies to variable or sta-
ble influenza H5N1 virus antigens, and may thus be of
value for use in passive immunotherapy for prophylaxis
and early treatment of influenza H5N1 infection. Influ-
enza A H5N1-specific F(ab')2 fragments may potentially
be used for the early treatment of avian influenza patients
to reduce the severity of illness and the likelihood of
H5N1 transmission to others.
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